Andrew Cheng is CEO & President at Akero Therapeutics, Inc. (AKRO). They have made 26 open-market trades across 1 company since 2021, most recently 2025-12-09.
CIK 0001778307
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 26 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKRO | SELL · 10b5-1 | 2025-10-10 | 2025-10-14 | $53.98 | $1.6M | -0.1% | +0.7% | N/A |
| AKRO | SELL · 10b5-1 | 2025-09-10 | 2025-09-12 | $43.13 | $2.4M | +9.8% | +24.1% | N/A |
| AKRO | SELL · 10b5-1 | 2025-08-11 | 2025-08-13 | $48.58 | $2.9M | -1.5% | -9.0% | +13.6% |
| AKRO | SELL · 10b5-1 | 2025-07-10 | 2025-07-11 | $51.16 | $3.1M | +0.1% | -6.8% | +4.4% |
| AKRO | SELL | 2025-06-18 | 2025-06-20 | $54.84 | $726K | -3.3% | -4.2% | -13.9% |
| AKRO | SELL · 10b5-1 | 2025-06-10 | 2025-06-12 | $54.04 | $4.1M | +5.5% | +1.0% | -17.1% |
| AKRO | SELL · 10b5-1 | 2025-05-12 | 2025-05-13 | $41.54 | $2.2M | +17.5% | +35.8% | +22.4% |
| AKRO | SELL · 10b5-1 | 2025-04-10 | 2025-04-11 | $35.23 | $1.1M | +11.9% | +13.4% | +42.0% |
| AKRO | SELL | 2025-03-12 | 2025-03-14 | $44.88 | $156K | -1.9% | -14.8% | +21.3% |
| AKRO | SELL · 10b5-1 | 2025-03-10 | 2025-03-12 | $41.79 | $1.3M | -0.8% | -21.5% | +20.0% |
| AKRO | SELL · 10b5-1 | 2025-02-10 | 2025-02-11 | $52.96 | $2.5M | +0.8% | -8.8% | -15.6% |
| AKRO | SELL · 10b5-1 | 2025-01-27 | 2025-01-29 | $54.90 | $3.3M | -8.2% | -11.9% | -22.8% |
| AKRO | SELL | 2024-12-10 | 2024-12-12 | $30.79 | $484K | +0.0% | -20.7% | +60.6% |
| AKRO | SELL · 10b5-1 | 2024-12-02 | 2024-12-04 | $32.09 | $1.6M | -4.9% | -8.2% | +44.8% |
| AKRO | SELL · 10b5-1 | 2024-11-01 | 2024-11-05 | $31.62 | $6.0M | -17.5% | -12.7% | +58.2% |
| AKRO | SELL · 10b5-1 | 2024-10-16 | 2024-10-18 | $31.41 | $5.7M | -0.8% | -4.5% | -22.4% |
| AKRO | SELL | 2024-09-10 | 2024-09-13 | $26.18 | $46K | +2.2% | +9.5% | +5.9% |
| AKRO | SELL | 2024-06-11 | 2024-06-13 | $22.64 | $357K | -5.2% | +13.4% | +5.9% |
| AKRO | SELL | 2024-03-13 | 2024-03-15 | $28.33 | $112K | -9.3% | -19.4% | -8.6% |
| AKRO | SELL · 10b5-1 | 2024-03-04 | 2024-03-06 | $32.86 | $4.9M | -11.8% | -23.7% | -36.8% |
| AKRO | SELL | 2023-12-14 | 2023-12-18 | $20.76 | $34K | +5.8% | -1.3% | +21.6% |
| AKRO | SELL | 2023-12-07 | 2023-12-11 | $20.01 | $946K | +12.8% | +17.9% | +48.1% |
| AKRO | SELL | 2023-10-02 | 2023-10-04 | $47.97 | $2.1M | -68.2% | -68.2% | -48.8% |
| AKRO | SELL | 2023-09-13 | 2023-09-25 | $50.34 | $169K | +4.0% | -73.9% | -48.0% |
| AKRO | SELL · 10b5-1 | 2023-09-01 | 2023-09-18 | $49.77 | $2.5M | -9.1% | -74.1% | -58.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.